BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has increased by 5.53 compared to its previous closing price of 6.85. However, the company has seen a 5.68% increase in its stock price over the last five trading sessions. Proactive Investors reported 2023-09-18 that BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d’excellence en santé et services sociaux (INESSS) has issued a positive recommendation for the reimbursement of its Orladeyo drug for the prevention of hereditary angioedema (HAE) attacks in adults and patients 12 years or older in Quebec. By 10:30am ET, the company’s shares were 6.5% higher at $7.30.
Is It Worth Investing in BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Right Now?
Moreover, the 36-month beta value for BCRX is 1.88. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price recommended by analysts for BioCryst Pharmaceuticals Inc. (BCRX) is $15.20, which is $7.87 above the current market price. The public float for BCRX is 183.35M and currently, short sellers hold a 22.53% of that float. On September 18, 2023, BCRX’s average trading volume was 2.66M shares.
BCRX’s Market Performance
BCRX’s stock has seen a 5.68% increase for the week, with a 3.27% rise in the past month and a -2.45% fall in the past quarter. The volatility ratio for the week is 4.00%, and the volatility levels for the past 30 days are at 4.14% for BioCryst Pharmaceuticals Inc. The simple moving average for the past 20 days is 2.12% for BCRX’s stock, with a -16.62% simple moving average for the past 200 days.
BCRX Trading at 0.89% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.15% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 4.00%, as shares surge +2.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.58% upper at present.
During the last 5 trading sessions, BCRX rose by +6.73%, which changed the moving average for the period of 200-days by -42.25% in comparison to the 20-day moving average, which settled at $7.09. In addition, BioCryst Pharmaceuticals Inc. saw -37.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from SANDERS MACHELLE, who sale 4,000 shares at the price of $7.98 back on Jun 15. After this action, SANDERS MACHELLE now owns 25,611 shares of BioCryst Pharmaceuticals Inc., valued at $31,920 using the latest closing price.
Hutson Nancy J, the Director of BioCryst Pharmaceuticals Inc., sale 12,866 shares at $8.04 during a trade that took place back on Jun 14, which means that Hutson Nancy J is holding 81,818 shares at $103,443 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -54.81 for the present operating margin
- +97.03 for the gross margin
The net margin for BioCryst Pharmaceuticals Inc. stands at -91.24. The total capital return value is set at -31.82, while invested capital returns managed to touch -53.21. Equity return is now at value 77.40, with -45.20 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 5.26, with the company’s debt to enterprise value settled at 0.30. The receivables turnover for the company is 6.77 and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To wrap up, the performance of BioCryst Pharmaceuticals Inc. (BCRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
